Nothing Special   »   [go: up one dir, main page]

MX2013007622A - Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson. - Google Patents

Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson.

Info

Publication number
MX2013007622A
MX2013007622A MX2013007622A MX2013007622A MX2013007622A MX 2013007622 A MX2013007622 A MX 2013007622A MX 2013007622 A MX2013007622 A MX 2013007622A MX 2013007622 A MX2013007622 A MX 2013007622A MX 2013007622 A MX2013007622 A MX 2013007622A
Authority
MX
Mexico
Prior art keywords
opioid
parkinson
disease
treatment
combination
Prior art date
Application number
MX2013007622A
Other languages
English (en)
Other versions
MX354125B (es
Inventor
Michael Hopp
Claudia Trenkwalder
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43903970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013007622(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of MX2013007622A publication Critical patent/MX2013007622A/es
Publication of MX354125B publication Critical patent/MX354125B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona una forma de dosificación farmacéutica que comprende un agonista opioide y un antagonista opioide para su uso en el tratamiento de la enfermedad de Parkinson. La presente invención también se refiere al uso de un agonista opioide y un antagonista opioide en dicha forma de dosificación.
MX2013007622A 2010-12-28 2011-12-27 Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson. MX354125B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10197210 2010-12-28
PCT/EP2011/074103 WO2012089738A1 (en) 2010-12-28 2011-12-27 A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease

Publications (2)

Publication Number Publication Date
MX2013007622A true MX2013007622A (es) 2013-12-06
MX354125B MX354125B (es) 2018-02-14

Family

ID=43903970

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007622A MX354125B (es) 2010-12-28 2011-12-27 Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson.

Country Status (19)

Country Link
US (1) US20140037729A1 (es)
EP (1) EP2658523A1 (es)
JP (2) JP5864606B2 (es)
KR (2) KR101632858B1 (es)
CN (1) CN103347495B (es)
AR (1) AR084620A1 (es)
AU (1) AU2011351447B2 (es)
BR (1) BR112013016862A2 (es)
CA (1) CA2822528C (es)
CL (1) CL2013001943A1 (es)
EA (1) EA025747B1 (es)
MX (1) MX354125B (es)
MY (1) MY162895A (es)
NZ (1) NZ612837A (es)
SG (1) SG191208A1 (es)
TW (2) TWI554271B (es)
UA (1) UA109301C2 (es)
WO (1) WO2012089738A1 (es)
ZA (1) ZA201304303B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103002882B (zh) 2010-05-10 2016-03-02 欧洲凯尔特公司 不含活性剂之颗粒及包含其之片剂的制备
CN103002881B (zh) 2010-05-10 2015-09-02 欧洲凯尔特公司 载有活性剂的颗粒与额外活性剂的组合
KR101632858B1 (ko) * 2010-12-28 2016-06-22 유로-셀티큐 에스.에이. 파킨슨병의 치료에 있어서 오피오이드 효능제와 오피오이드 길항제의 조합물
US9918980B2 (en) 2011-04-29 2018-03-20 Rutgers, The State University Of New Jersey Method of treating dyskinesia
EP2701707B1 (en) 2011-04-29 2020-09-02 Rutgers, the State University of New Jersey Method of treating dyskinesia
US10736889B2 (en) 2011-04-29 2020-08-11 Rutgers, The State University Of New Jersey Method of treating dyskinesia
US10071088B2 (en) 2012-06-26 2018-09-11 Precondit, Llc Anti-nausea drug combinations
KR20160034352A (ko) * 2013-07-23 2016-03-29 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
UA116405C2 (uk) * 2013-11-13 2018-03-12 Євро-Селтік С.А. Гідроморфон та налоксон для лікування болю та синдрому опіоїдної дисфункції кишечнику
CA2847781C (en) * 2014-03-28 2019-03-12 Purdue Pharma Reducing drug liking in a subject
WO2015187932A1 (en) * 2014-06-04 2015-12-10 Mentinova Inc. Compositions and methods of reducing sedation
WO2016029218A1 (en) 2014-08-22 2016-02-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Substituted 1-arylethyl-4-acylaminopiperidine derivatives as opioid/alpha-adrenoreceptor modulators and method of their preparation
CA2974055A1 (en) * 2015-01-23 2016-07-28 Euro-Celtique S.A. A combination of hydromorphone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk forintestinal bacterial translocation
US20160256451A1 (en) * 2015-03-06 2016-09-08 Develco Pharma Schweiz Ag Dosage of naloxone
ES2869981T3 (es) * 2015-05-26 2021-10-26 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Composiciones para su uso en el tratamiento de la enfermedad de parkinson y trastornos relacionados
US20180104236A1 (en) * 2016-09-26 2018-04-19 Euro-Celtique S. A. Methods of treatment comprising administering a high daily dose of oxycodone and naloxone in a 2:1 weight ratio
CA3149152A1 (en) 2019-08-11 2021-02-18 Kappa-Pharma LLC Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates
WO2021087456A1 (en) * 2019-10-31 2021-05-06 Fung Constance H Methods, systems, and apparatus for tapering or uptitrating drug dosages

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
EE05171B1 (et) * 2000-02-08 2009-06-15 Euro-Celtique, S.A. Peroraalne ravimvorm, mis sisaldab opioidagonisti vabanevas vormis ja eraldatud opioidantagonisti, meetod selle valmistamiseks ning selle kasutamine meditsiinis
MXPA02003670A (es) * 2000-07-13 2003-01-28 Euro Celtique Sa Sales y bases de 17-(ciclopropilmetil)-4,5 alfa-epoxi-6-metilenomorfinan-3,14 diol para optimizar la homeostasis de dopamina durante la administracion de analgesicos.
SI1416842T1 (sl) * 2001-07-18 2009-06-30 Euro Celtique Sa Farmacevtske kombinacije oksikodona in naloksona
US20060177381A1 (en) * 2002-02-15 2006-08-10 Howard Brooks-Korn Opiopathies
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
US20070232638A1 (en) * 2006-04-03 2007-10-04 Howard Brooks-Korn Opiopathies
WO2009132313A2 (en) * 2008-04-25 2009-10-29 Progenics Pharmaceuticals, Inc. Morphinan derivatives of organic and inorganic acids
PE20110422A1 (es) * 2008-07-07 2011-07-01 Euro Celtique Sa Composicion farmaceutica que comprende antagonistas opioides
MX347106B (es) * 2009-03-10 2017-04-12 Euro-Celtique S A * Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona.
GB0909680D0 (en) * 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
KR101632858B1 (ko) * 2010-12-28 2016-06-22 유로-셀티큐 에스.에이. 파킨슨병의 치료에 있어서 오피오이드 효능제와 오피오이드 길항제의 조합물

Also Published As

Publication number Publication date
WO2012089738A1 (en) 2012-07-05
NZ612837A (en) 2014-11-28
CA2822528C (en) 2017-07-18
SG191208A1 (en) 2013-07-31
CL2013001943A1 (es) 2013-11-29
TW201302199A (zh) 2013-01-16
ZA201304303B (en) 2014-02-26
JP2016040268A (ja) 2016-03-24
CN103347495A (zh) 2013-10-09
EA201390977A1 (ru) 2013-12-30
JP5864606B2 (ja) 2016-02-17
BR112013016862A2 (pt) 2016-10-04
US20140037729A1 (en) 2014-02-06
EP2658523A1 (en) 2013-11-06
AR084620A1 (es) 2013-05-29
TWI554271B (zh) 2016-10-21
CN103347495B (zh) 2017-06-20
KR20150076262A (ko) 2015-07-06
AU2011351447B2 (en) 2016-02-25
UA109301C2 (uk) 2015-08-10
KR101632858B1 (ko) 2016-06-22
AU2011351447A1 (en) 2013-07-25
EA025747B1 (ru) 2017-01-30
MX354125B (es) 2018-02-14
KR101618929B1 (ko) 2016-05-09
JP6074003B2 (ja) 2017-02-01
MY162895A (en) 2017-07-31
JP2014501268A (ja) 2014-01-20
CA2822528A1 (en) 2012-07-05
KR20130106431A (ko) 2013-09-27
TW201628618A (zh) 2016-08-16

Similar Documents

Publication Publication Date Title
MX2013007622A (es) Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson.
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
IN2015KN00414A (es)
IN2012DN06720A (es)
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
EA201400246A1 (ru) Новая, не допускающая злоупотребления фармацевтическая композиция для лечения опиоидной зависимости
EP2406765A4 (en) DEVICE FOR ADMINISTERING A MEDICAMENT TO A PATIENT WITH RESTRICTED PATIENT-SIDED ACCESS TO THE MEDICAMENT IN THE CASE OF CONTRAINDICATIONS AND APPLICATION METHOD THEREFOR
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
IN2012DN02177A (es)
IN2012DN00754A (es)
EP2528603A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS
JO3078B1 (ar) مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة
IN2015DN01164A (es)
MX348933B (es) Composiciones, formas de dosificacion y coadministracion de un compuesto agonista opioide y un compuesto analgesico.
TN2012000488A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
EA201390653A1 (ru) Aa антагонисты как усилители когнитивной и моторной функций
PH12016500666A1 (en) Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
SI2379066T1 (sl) Uporaba opioidnih antagonistov za pripravo zdravila za zdravljenje degenerativnih bolezni retine
GB201210686D0 (en) V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
HK1203391A1 (en) Administration of an antagonist of alpha 5 beta1 for anti- antiogenesis and cancer treatment 51
SG10201801200PA (en) An h3 receptor antagonist for use in the treatment of alzheimer's disease
PH12014501390A1 (en) Novel therapeutic use of p75 receptor antagonists
IN2014DN09359A (es)

Legal Events

Date Code Title Description
FG Grant or registration